---
title: "Hong Kong Stock Movement: XUANZHUBIO-B surged 21.41%, driven by dual tumor digestion boosting commercialization explosion"
description: "XUANZHUBIO-B surged 21.41%; CSPC Pharmaceutical Group fell 1.44%, with a transaction volume of HKD 534 million; China National Pharmaceutical Group fell 0.54%, with a transaction volume of HKD 398 mil"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/261996996.md"
published_at: "2025-10-21T07:37:41.000Z"
---

# Hong Kong Stock Movement: XUANZHUBIO-B surged 21.41%, driven by dual tumor digestion boosting commercialization explosion

> XUANZHUBIO-B surged 21.41%; CSPC Pharmaceutical Group fell 1.44%, with a transaction volume of HKD 534 million; China National Pharmaceutical Group fell 0.54%, with a transaction volume of HKD 398 million; Heng Rui Medicine fell 1.20%, with a transaction volume of HKD 228 million; Hansoh Pharmaceutical fell 1.32%, with a market value of HKD 217.6 billion

**Hong Kong Stock Movement**

XUANZHUBIO-B surged 21.41%. According to recent important news:

1.  On October 21, XUANZHUBIO-B rose over 14% in the afternoon, reaching a high of HKD 38.8, an increase of over 234% from the IPO price of HKD 11.6. The company has more than ten drug assets actively under development, covering digestive system diseases, tumors, and non-alcoholic fatty liver disease (NASH), including three NDA-approved assets. This news significantly boosted the stock price. Source: Dolphin Research APP
    
2.  On October 21, Dolphin Research APP pointed out that with the dual drivers of digestion and tumors, XUANZHUBIO is expected to enter a commercialization explosion period in 2025. The core tumor drugs Pyrotinib and Dirocitinib have been consecutively approved, along with the previously approved proton pump inhibitor Anaprazole Sodium, forming a commercial "three-horse carriage" product matrix that has gained market recognition. Source: Dolphin Research APP
    
3.  On October 18, traditional Chinese medicine varieties such as Niuhuang Qinggan Capsules received secondary protection approval, prompting companies to increase R&D investment and enhance product competitiveness. This news has a positive impact on the development of the traditional Chinese medicine industry. Source: Artery Network
    

**Stocks with High Trading Volume in the Industry**

Shiyao Group fell 1.44%. According to recent important news:

1.  On October 20, Shiyao Group's JSKN003, developed in collaboration with CanSino Biologics, received breakthrough therapy designation from the National Medical Products Administration for the treatment of HER2-positive advanced colorectal cancer patients. This news caused stock price fluctuations, with a trading volume of HKD 534 million. Source: Caihua News
    
2.  On October 18, Shiyao Group made progress in its patent dispute in the United States, as the U.S. Patent and Trademark Office accepted Shiyao Group's request to invalidate Lepu Biotech's patent. This event may affect market confidence in Shiyao Group. Source: Dolphin Research
    
3.  On October 20, Shiyao Group's shareholder equity disclosure showed slight changes in shareholding ratios, which may attract market attention. Source: Dolphin Research
    

China Biopharmaceutical fell 0.54%. According to recent news:

1.  On October 21, China Biopharmaceutical announced the interim analysis results of the Phase III clinical study of Cumosil Capsules for HR+/HER2- advanced breast cancer at the 2025 European Society for Medical Oncology Congress. The drug showed significant efficacy, delaying clinical resistance issues and reducing bone marrow suppression, becoming a potential best-in-class therapy. This news caused stock price fluctuations.
    
2.  On October 19, research results showed that the median overall survival of Cumosil trial participants reached 35.81 months, setting a historical high and providing new treatment directions for refractory breast cancer patients. This news further influenced market sentiment.
    
3.  On October 21, investment banks rated China Biopharmaceutical primarily as a buy, with 13 investment banks giving buy ratings in the past 90 days, and the average target price set at HKD 10.07 CMB International's latest research report gives a buy rating with a target price of HKD 9.4. This rating information has an impact on the stock price. The chemical pharmaceutical industry has performed strongly recently, with significant capital inflow.
    

Hengrui Medicine fell by 1.20%. According to recent important news:

1.  On October 18, Hengrui Medicine announced an international patent application titled "Method for Treating TSLP-Related Inflammatory Diseases with Anti-TSLP Antibodies," demonstrating the company's ongoing investment in R&D, which may have a positive impact on the stock price. Data source: Qichacha
    
2.  On October 20, Hengrui's oncology division achieved a technological breakthrough in the global market, successfully entering the international market, further consolidating its leading position in cancer treatment, which may boost market confidence. Data source: Hengrui Medicine
    
3.  No other significant news recently. The pharmaceutical industry is highly competitive, with increased R&D investment.
    

**Stocks ranked among the top in industry market capitalization**

Hansoh Pharmaceutical fell by 1.32%. According to recent important news:

1.  On October 20, Hansoh Pharmaceutical signed a licensing agreement for HS-20110 with Roche, receiving an upfront payment of USD 80 million and up to USD 1.45 billion in milestone payments, driving stock price fluctuations. Source: Haitong International
    
2.  On October 20, Nomura Securities raised its revenue and profit forecasts for Hansoh Pharmaceutical for 2026, with a slight increase in the target price to HKD 35.50, maintaining a neutral rating. Source: Nomura Securities
    
3.  On October 18, Hansoh Pharmaceutical received an AA rating in the ESG ranking of the Huazheng Index, ranking 4th among Hong Kong-listed pharmaceutical companies. Source: Huazheng Index. Innovative drugs are favored by the capital market, and industry competition is intensifying

### Related Stocks

- [02575.HK - XUANZHUBIO-B](https://longbridge.com/en/quote/02575.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 港股異動：軒竹生物-B 漲 12.98%，新總經理上任能否穩住市場信心？ | 軒竹生物-B 漲 12.98%；翰森製藥漲 4.25%，成交額達到 13.83 億港幣；石藥集團漲 2.37%，成交額達到 5.75 億港幣；中國生物製藥漲 1.52%，成交額達到 1.68 億港幣；恆瑞醫藥漲 4.23%，市值達到 515 | [Link](https://longbridge.com/en/news/271726969.md) |
| 港股異動：軒竹生物-B 暴跌 15.34%，高管辭任引發市場擔憂 | 軒竹生物-B 跌 15.34%；石藥集團漲 3.89%，成交額達到 6.14 億港幣；中國生物製藥漲 3.30%，成交額達到 3.12 億港幣；恆瑞醫藥漲 2.83%，成交額達到 1.78 億港幣；翰森製藥漲 3.90%，市值達到 2292 | [Link](https://longbridge.com/en/news/271457426.md) |
| 威斯康星大學麥迪遜分校要求學生報告麻疹疫苗接種情況 | 威斯康星大學麥迪遜分校已要求學生披露其麻疹、腮腺炎和風疹等疾病的疫苗接種狀態，此舉是在校園內出現近期麻疹病例後實施的。該政策旨在增強公共健康意識，併為高風險學生提供更好的支持。此公告是在全國麻疹病例增加的背景下發布的，衞生官員呼籲進行疫苗接 | [Link](https://longbridge.com/en/news/275930065.md) |
| 07:00 ETInVera Medical 的新型靜脈輸液設備獲得歐洲 CE 認證批准 | 愛爾蘭醫療科技公司 InVera Medical 已獲得 CE 標誌認證，推出其新款 InVera 輸液裝置，該裝置旨在對患病的腿部靜脈進行微創治療，包括靜脈曲張。該設備能夠有效地進行治療，無需熱療方法，僅需局部麻醉且不需要專門的醫院設備。 | [Link](https://longbridge.com/en/news/275896024.md) |
| 11:03 ET InVera Medical 獲得歐洲 CE 認證用於其新型靜脈輸液設備 | 愛爾蘭醫療科技公司 InVera Medical 已獲得歐洲 CE 認證，推出一種新的微創設備，旨在有效治療患病的腿部靜脈，包括靜脈曲張。該認證使公司能夠在歐盟範圍內銷售 InVera 輸注設備。與現有的燒灼靜脈技術不同，InVera 設備 | [Link](https://longbridge.com/en/news/275924536.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.